Evaluation of Minimal Residual Disease as a Surrogate for Progression-Free Survival in Hematology Oncology Trials: A Meta-Analytic Review

Documenti analoghi

• Evaluation of Individual and Trial Level Association Metrics in the Validation of a Binary Surrogate Endpoint for a True Time-to-Event Endpoint
  di: Ge, Renee Y., et al.
  Pubblicazione: (2026)
• Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
  di: Long, James P., et al.
  Pubblicazione: (2025)
• Evaluation of Surrogate Endpoints Based on Meta-Analysis with Surrogate Indices
  di: Stijven, Florian, et al.
  Pubblicazione: (2025)
• Distribution-Free Selection of Low-Risk Oncology Patients for Survival Beyond a Time Horizon
  di: Sesia, Matteo, et al.
  Pubblicazione: (2025)
• On Assessing Overall Survival (OS) in Oncology Studies
  di: Hsu, Jason C.
  Pubblicazione: (2025)